Condition: Migraine · Sponsor: Aspeya, Inc.
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither participants nor study staff will know which treatment is given at the time. The medication is taken using a handheld dry powder inhaler to treat migraine attacks when they occur. Following screening, eligible participants will be enrolled and randomized to one of two treatments sequences i.e. one treatment sequence will receive ASY202 in treatment period 1 followed by placebo in treatment period 2 and other treatment sequence will receive placebo in treatment period 1 followed by ASY202 in treatment period 2. The study lasts about 16 weeks and includes a screening period, two treatment periods (with a minimum of 7 days washout period between the treatment periods), and a safety follow-up visit.
This description comes directly from the study's public registry record.
Eken · +41 76 358 88 30 · clinicaltrials@aspeya.com
Always discuss trial participation with your own doctor first.
| Sunwise Clinical Research, Llc | Walnut Creek, California, United States | Recruiting |
| Clinical Neuroscineces Solutions - Orlando | Orlando, Florida, United States | Not Yet Recruiting |
| Clinical Neuroscineces Solutions | Orlando, Florida, United States | Not Yet Recruiting |
| M3 Wake Research - Las Vegas Rainbow | Las Vegas, Nevada, United States | Not Yet Recruiting |
| Clinical Research Associates, Inc. | Nashville, Tennessee, United States | Not Yet Recruiting |
| Highland Research | Salt Lake City, Utah, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07646613